Adipogen/Tofacitinib/AG-CR1-3625-M005/5 mg
商品编号：
AG-CR1-3625-M005
品牌：
Adipogen Inc
市场价：
¥1200.00
美元价：
720.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | CP-690550;Xeljanz;Tasocitinib |
| ProductType | Chemical |
| Properties | |
| Formula | C16H20N6O |
| MW | 312.4 |
| CAS | 477600-75-2 |
| PurityChemicals | ≥98% |
| Appearance | Off-whitetopaleyellowsolid. |
| Solubility | SolubleinDMSOorethanol. |
| InChiKey | UJLAWZDWDVHWOW-YPMHNXCESA-N |
| ShippingandHandling | |
| Shipping | AMBIENT |
| ShortTermStorage | +4°C |
| LongTermStorage | -20°C |
| HandlingAdvice | Keepcoolanddry. Protectfrommoistureandoxygen. |
| Use/StABIlity | Stableforatleast2yearsafterreceiptwhenstoredat-20°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
- PotentcellpermeableJAK3inhibitor(IC50=1nM).ShowsalsoJAK-1inhibitoryactivity.
- Immunosuppressiveandanti-inflammatoryagent.
- InhibitssignalingthroughheterodimericreceptorsassociatedwithJAK3,JAK1,orbothofthem,withfunctionalselectivityoverJAK2-pairedreceptors.BlocksdownstreamSTATsignaling,resultinginpotentinhibitionofseveralcytokines,includinginterleukins2,4,7,9,15and21,whichareintegraltolymphocyteactivation,functionandproliferation.
- Investigatedforseveralautoimmunedisordersincluding,rheumatoidarthritisandpsoriasis.
- PotentandselectiveinhibitorofHIV-1replicationandvirusreactivationinvitro.
ProductReferences
- PreventionoforganallograftrejectionbyaspecificJanuskinase3inhibitor:P.S.Changelian,etal.;Science302,875(2003)
- ImmunosuppressionbytheJAK3inhibitorCP-690,550delaysrejectionandsignificantlyprolongskidneyallograftsurvivalinnonhumanprimates:D.C.Borie,etal.;Transplantation79,791(2005)
- CombineduseoftheJAK3inhibitorCP-690,550withmycophenolatemofetiltopreventkidneyallograftrejectioninnonhumanprimates:D.C.Borie,etal.;Transplantation80,1756(2005)
- TheJAK-3inhibitorCP-690550isapotentanti-inflammatoryagentinamurinemodelofpulmonaryeosinophilia:E.Kudlacz,etal.;Eur.J.Pharmacol.582,154(2008)
- CP-690550,aJAK3inhibitorasanimmunosuppressantforthetreatmentofrheumatoidarthritis,transplantrejection,psoriasisandotherimmune-mediateddisorders:K.West;Curr.Opin.Investig.Drugs10,491(2009)(Review)
- DiscoveryofCP-690,550:apotentandselectiveJanuskinase(JAK)inhibitorforthetreatmentofautoimmunediseasesandorgantransplantrejection:M.E.Flanagan,etal.;J.Med.Chem.53,8468(2010)
- CP-690,550,atherapeuticagent,inhibitscytokine-mediatedJak3activationandproliferationofTcellsfrompatientswithATLandHAM/TSP:W.Ju,etal.;Blood117,1938(2011)
- Modulationofinnateandadaptiveimmuneresponsesbytofacitinib(CP-690,550):K.Ghoreschi,etal.;J.Immunol.186,4234(2011)
- InhibitoryeffectsoftheJAKinhibitorCP690,550onhumanCD4(+)Tlymphocytecytokineproduction:K.Migita,etal.;BMCImmunol.12,51(2011)
- JAKinhibitortofacitinibfortreatingrheumatoidarthritis:frombasictoclinical:Y.Tanaka&K.Yamaoka;Mod.Rheumatol.23,415(2013)(Review)
- RuxolitinibandtofacitinibarepotentandselectiveinhibitorsofHIV-1replicationandvirusreactivationinvitro:C.Gavegnano,etal.;Antimicrob.AgentsChemother.58,1977(2014)
- Tofacitinib,aJAKinhibitor,inhibitshumanBcellactivationinvitro:S.P.Wang,etal.;Ann.Rheum.Dis.73,2213(2014)
- TheJAKinhibitortofacitinibsuppressessynovialJAK1-STATsignallinginrheumatoidarthritis:D.L.Boyle,etal.;Ann.Rheum.Dis.74,1311(2015)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
